Status:
ACTIVE_NOT_RECRUITING
A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
Lead Sponsor:
Bayer
Conditions:
Neovascular Age-related Macular Degeneration (nAMD)
Diabetic Macular Edema (DME)
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied. In observational s...
Eligibility Criteria
Inclusion
- Patients who are prescribed aflibercept 8 mg during the observable period from the collected data.
Exclusion
- Patients in the nAMD cohort or nAMD and DME cohort who have the ICD-10 codes for nAMD who are aged \<40 years old.
- Patients in the DME cohort or others who are aged \<18 years old.
- Female patients who have any pregnancy-related records.
- Patients who do not have at least 365 days of continuous enrollment in the database.
Key Trial Info
Start Date :
April 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2027
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06929143
Start Date
April 14 2025
End Date
July 30 2027
Last Update
December 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer
Osaka, Japan, 5300001